---
layout: post
title: "北陆药业：获得碘海醇注射液《药品补充申请批准通知书》"
date: 2022-04-06 16:10:07 +0800
categories: zhengquanshibao·quanzhongshe
tags: 证券时报·券中社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.300016" data-code="300016|0|2" data-code2="300016|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.300016&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 300016_0" data-code="K 300016|0|2" data-code2="K 300016|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>北陆药业公告，近日，公司收到国家药品监督管理局颁发的关于碘海醇注射液(100ml:35g按碘(I)计)的《药品补充申请批准通知书》，增加南京化学试剂股份有限公司作为该药品依地酸钙钠的辅料供应商。</p><p class="em_media">（文章来源：证券时报·券中社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204062333614067>

[返回证券时报·券中社新闻](//finews.withounder.com/category/zhengquanshibao·quanzhongshe.html)｜[返回首页](//finews.withounder.com/)